文献

J-GLOBAL ID：201802282021782517   整理番号：18A0361328

隔週の皮下トシリズマブへの不適切な応答の関節リウマチ患者における皮下トシリズマブ単剤療法の投与間隔の短縮の無作為化,二重盲検,並行群間第III相試験:12週二重盲検期間の結果

A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period

著者 (7件)： OGATA Atsushi (Osaka Univ. Graduate School of Medicine, Osaka, JPN) ,  OGATA Atsushi (NTT West Osaka Hospital, Osaka, JPN) ,  TANAKA Yoshiya (Univ. Occupational and Environmental Health, Kitakyushu, JPN) ,  ISHII Tomonori (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  KANEKO Motohide (Kaneko Internal Medicine Rheumatology Clinic, Kawaguchi, JPN) ,  MIWA Hiroko (Chugai Pharmaceutical Co., Ltd., Tokyo, JPN) ,  OHSAWA Shino (Chugai Pharmaceutical Co., Ltd., Tokyo, JPN)
資料名： Modern Rheumatology  (Modern Rheumatology)
巻： 28  号： 1  ページ： 76-84  発行年： 2018年01月 
JST資料番号： L5142A  ISSN： 1439-7595  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： イギリス (GBR)  言語： 英語 (EN)

抄録/ポイント： ・隔週(q2w)の皮下トシリズマブ(TCZ-SC)に対して不...

シソーラス用語： *モノクローナル抗体 ,...
準シソーラス用語： *トシリズマブ ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A0361328&from=J-GLOBAL&jstjournalNo=L5142A") }}

分類 (1件)： 運動器系疾患の薬物療法  (GG05020D)

引用文献 (21件)：

• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-23.
• Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-80.
• Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
• Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609-21.
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-97.

タイトルに関連する用語 (10件)： トシリズマブ ,  応答 ,  関節リウマチ ,  患者 ,  単剤 ,  療法 ,  投与間隔 ,  二重盲検 ,  並行 ,  第III相試験